Friday 11 September 2015

Circulating Tumor Cells (CTC) - Set to Become a Regular Screening Test for Cancers

Just as common as colonoscopies and mammograms, Circulating Tumor Cells (CTC) Screening may become a regular affair for many types of cancers.
http://www.einpresswire.com/article/285181960/circulating-tumor-cells-ctc-set-to-become-a-regular-screening-test-for-cancers

HYDERABAD, TELANGANA, INDIA, September 8, 2015 /EINPresswire.com/ -- Since cancer is a disease of genetic mutations, the future treatments will be based on assessing how the mutation leads to cancer. Cells within a single cancer tumor may possess different mutations, and hence several targeted therapies are imperative for treating even a single type of cancer. The challenge is to develop techniques for preventing cancer and identifying cancer at its earliest stages (when cancer is more treatable). Since the average life expectancy of the world’s population is increasing, the chances of developing cancer also increase. CTC Screening is slated to be an effective mechanism for identifying cancer at its earliest stages and thereby reducing cancer deaths. 

RI Technologies' market research report on Circulating Tumor Cells (CTC) Technologies gives a market insight into technologies and services used for cancer detection. The market is analyzed by Cancer type into Prostate, Breast and Other; and by Function into Prognostics, Diagnostics and Therapy Management. The report serves as a guide to CTC markets, covering more than 150 companies that are engaged in CTC studies/screening, products and services. Major Contract Research Organizations, Research Institutes and Universities serving the CTC market are also covered in the corporate directory section of this report. Information related to recent product releases, product developments, partnerships, collaborations, and mergers and acquisitions is covered in the report. Compilation of Worldwide Patents related to CTC Technologies is also provided. A global perspective is presented along with regional analysis covering the regions of North America, Europe, and Asia-Pacific. 

The biggest technical challenge is CTC detection despite the continued development of many new technologies. The key need is for a technology that will detect the real metastasis-initiating CTC which in turn will trigger distant metastases. This may be a combination of complementary technologies or even several technologies optimized for specific tumor types. CTC enrichment depends on the different properties of CTCs that distinguish them from the surrounding normal hematopoietic cells; physical properties; and biological properties. Most of the current technologies are still based on epithelial cell adhesion molecule (EpCAM) expression. New emerging technologies may try to capture EpCAM-negative CTCs.

Global CTC Technologies market is predicted to cross US$ 12 billion by the year 2020. The worldwide cancer incidence rate is growing alarmingly. As per statistics, the number of global cancer deaths is projected to increase about 45-50% (about 8 million deaths) from 2007 to 2030 (about 12 million deaths). This is due to increasing and aging populations worldwide. Cancer is the second largest cause of death in most developed countries after cardiovascular disease, and developing countries too are now showing the same pattern. Unless tobacco controls are strictly followed, lung cancer will continue to kill more people than any other cancer. Prostate, breast and colon cancers are more common in developed countries, while liver, cervical and stomach cancers are more common in developing countries. 


To order this market research report on CTC Technologies, please contact us at contactus@researchimpact.com. You may also explore customized research services on CTC Technologies with RI Technologies. 


About RI Technologies

RI Technologies, www.researchimpact.com, is a premier market research provider. The company believes in pure research that will trigger action for immediate customer needs rather than plain reporting of data. The reports provide strategic information tools that help to probe into and support critical business decisions. RI Technologies believes in broadening the value of market research obtained through several dedicated streams of information. Investment banks, companies, management consultants, trade associations, corporate executives, business analysts, libraries, universities, and business schools stand to benefit from RI Technologies' unique market research reports.


contactus@researchimpact.com

www.researchimpact.com
RI Technologies
+91 9676994272

Thursday 20 August 2015

DNA Vaccines - Latest Breakthrough in the Field of Molecular Technology

Prevention of diseases by immunization saves money from wastage on post-disease therapeutic agents like antibiotics. The induced immunity alleviates the sufferings of animals from diseases. Immunization has saved countless number of animals worldwide from premature mortality. The products derived from vaccinated animals are safe and do not pose any health hazard to human consumers. Vaccination has not only prevented the occurrence of many diseases, but also has eradicated certain human and animal diseases totally.
The principle of vaccination was evolved more than two centuries ago. Since then, rapid progress has been achieved in the preparation of vaccines. The vaccine, when first injected, triggers the immune system of the recipient to produce antibodies against the infectious agent. This primary vaccination course for dogs and cats involves two or more administrations because of variations in the MDA levels encountered in individuals. Certain vaccines against diseases, as for example Leptospirosis, are given twice to produce sufficient titer of antibodies in the serum of the recipients. Booster doses of vaccination are given to maintain adequate level of serum antibodies.
RI Technologies' Veterinary Vaccines market research report covers the Types of Veterinary Vaccines and the different Species for which Vaccines are present in the market. The Types of Veterinary Vaccines covered include Live Attenuated, Inactivated, Recombinant and Other (Conjugate Vaccines, DNA Vaccines, Toxoids etc). The Species include Bovine, Porcine, Poultry, Canine & Feline, Ovine & Caprine and Other (Equine, Fish, Wild Animals etc.). The study includes estimates and projections for the total global Veterinary Vaccines market and also key regional markets that include Europe, North America, Asia-Pacific Latin America, Middle East and Rest of World. Estimates and projections are illustrated graphically.
Business profiles of 13 major companies are discussed in the report. The report serves as a guide to global Veterinary Vaccines industry, covering 365 companies that are engaged in the development and supply of Veterinary Vaccines.Information related to recent product releases, product developments, partnerships, collaborations, and mergers and acquisitions is also covered in the report.
please contact us.
Anasuya Vemuri
+91 9676994272

Monday 17 August 2015

Bioimaging - A Prominent Advancement in the Field of Biomedical Research

Pharmaceutical industries make use of the imaging output obtained from simple microphotograph to sophisticated images obtained through MRI, CT, PET, X-ray, and sonography. Pharmocological researchers are focusing their attention on MRI and PET scans. The application of these imaging techniques is expected to boost productive drug research and help in the assessment of the suitability of a specific drug for treatment of human diseases. Among the imaging techniques, PET occupies the place of first choice in drug research. The researchers use radiopharmaceuticals labeled with positron emitting radionuclides. By measuring the annihilation radiation using a coincidence technique, pharmacokinetics of the drug used and its effect on metabolism can be evaluated. In drug discovery, it is important to evaluate the biological effect of the drug, its comparative efficacy, its binding affinity, and its accumulation in the target organ in effective concentration. Such valuable information could be gathered by means of using PET scan.
Bioimaging techniques are regarded as the most promising advancements in the field of present day healthcare and biomedical research. This is being recognized as one of the most comprehensive achievements, which has eased the working conditions of the physicians. In the present medical scenario majority of the diseases are being diagnosed and attended using biomedical imaging techniques. This technique requires a good amount of development to understand the basic functions of the organs in the living system. The main aim of the concept of bioimaging is to provide an effective understanding of the numerous available imaging modalities like X-ray, Commuted Tomography, Emission Tomography and Magnetic Resonance Imaging. This is done by relating the basic operating principles of these techniques with that of Imaging techniques.
RI Technologies' Global Market Research Report on Bioimaging focuses on the different types and modalities of bioimaging and their application in Research and Development and Diagnostics. The study provides global market analysis for bioimaging by Modalities including Ultrasound, CT, MRI, PET, SPECT and other modalities comprising X-Ray, TEM and OCT. The study includes estimations and predictions for the total global bioimaging market. Information related to recent product releases, product developments, partnerships, collaborations, and mergers and acquisitions is covered in the report. Compilation of Worldwide Patents and Research related to Bioimaging is also provided. A global perspective is presented in Bio Imaging Market size along with regional analysis covering North America, Europe, Asia-Pacific, Latin America, and Rest of World.
For more information on this report please contactus -   
Anasuya Vemuri
RI Technologies

Wednesday 12 August 2015

Prion diseases such as Bovine Spongiform Encephalopathies (BSE) and the variant Creutzfeldt-Jakob Disease (vCJD) pose considerable health risks to human beings.

Prions research studies are gaining importance. The neurodegenerative diseases in animals and humans caused by prions are fatal and are still incurable to date.

Prions are classified depending on the resistance that they offer to traditional inactivation practices like dry heat, boiling, irradiation, and chemical treatment. The prion infectivity observed in purified samples is reduced owing to repeated digestion with proteases. Similarly, the results obtained from boiling in sodium dodecyl sulfate and urea also indicate varying values. The other process, which has greatly influenced the inactivation procedure, is the denaturing process. The experiments carried out using organic solvents like phenol or chaotropic reagents have indicated that this process enables inactivation partially. In addition, the various traditional methods available did not help in achieving complete inactivation of prions.

http://www.einpresswire.com/article/280741782/prions-global-market-research-report-ri-technologies-update


Tuesday 28 July 2015

Glucosamine: A Longevity Extending Therapeutic and a Dietary Supplement

Investigations at ETH Zurich and four research institutions at Germany carried out by Michael Ristow and colleagues on animal models have revealed that glucosamine could affect longevity as well as could be used as supplement in a diet low on carbohydrates.
Glucosamine, an easily obtainable supplement at the pharmacy, is a well known therapeutic for arthritis as well as a preventive measure for degeneration of joints. Demonstrated about 50 years back glucosamine is also known to decrease the metabolic rate of nutritive sugars. Glucosamine has also shown to be effective in delaying development of carcinoma.
In a research carried out by Michael Ristow in 2007 on roundworms, model organisms for research related to aging, while high concentrates of nutritive sugars affected the lifetime of the worms, inhibition of metabolic process of the carbohydrates however improved their longevity. The methodology though was not applicable for studies on rodent models.
In a recent publication, Ristow and colleagues have stated that studies at Zurich and Germany resulted in a 5% extension of lifespan of roundworms treated with glucosamine in comparison to the control group. The studies on aging mice, with a control group, wherein the mice received identical diets with the experimental group receiving an additional glucosamine supplement, revealed that glucosamine could extend the longevity of the mice by 10%. The mice used for the investigations were 100 weeks old a comparative 65 years of human being. A 10% extension of longevity could mean another 8 years added to the lifetime of a human being.
The studies have also revealed that glucosamine could improve metabolic rates of glucose in the aging mice, suggesting a preventive measure in the development of diabetes.
Investigations also revealed that glucosamine could mimic a low carbohydrate diet and encourage the preferential amino acid metabolism associated with the latter, suggesting that glucosamine could be taken up as dietary supplement by human beings.

Epidemiological studies involving a study group of more than 77,000, carried out recently in two phases, have demonstrated improved longevity in human beings with glucosamine as a dietary supplement. While there hasn't been a definitive proof about the effects of glucosamine on human beings, compared with lifespan-extending therapeutics that could result in side effects, Ristow suggested that glucosamine could with its potentiality be added as a dietary supplement for the human being.


For more information, please visit www.researchimpact.com



Tuesday 2 June 2015

Intravenous Solutions Market Research Report from RI Technologies Explores Key Strategic Developments

http://www.einpresswire.com/article/268588330/intravenous-solutions-market-research-report-from-ri-technologies-explores-key-strategic-developments

Light and portable injection devices have become handy as patients can now receive intravenous treatments in doctor’s clinics or even in their own homes.
According to hospital supply companies and nutritionists, almost 80% of patients are deprived of the beneficial effects that could be gained from a wider use of existing intravenous nutrition.
— Anasuya Vemuri
HYDERABAD, TELANGANA, INDIA, June 2, 2015 /EINPresswire.com/ -- Intravenous Solutions Market Research Report from RI Technologies covers the types of Intravenous Solutions and the various nutrients present in Intravenous Solutions in the market. The types of Intravenous Solutions covered include Partial Parenteral Nutrition and Total Parenteral Nutrition. The nutrients present in Intravenous Solutions include Carbohydrates, Salt and Electrolytes, Minerals and Vitamins, Amino Acids and Other (such as Fat Emulsions, Plasma extenders, Antibiotics and IVIG). The report provides an in depth analysis of each of the types and nutrients by their respective categories. The study includes estimates and projections for the total global Intravenous Solutions market and also key regional markets that include North America, Europe, Asia-Pacific and Rest of World. Estimates and projections are illustrated graphically. Business profiles of 15 major companies are discussed in the report. The report serves as a guide to global Intravenous Solutions industry, as it covers more than 150 companies that are engaged in the development and supply of Intravenous Solutions products and services. Information related to recent product releases, product developments, partnerships, collaborations, and mergers and acquisitions is also covered in the report.

The market research report on Intravenous Solutions is available at http://www.researchimpact.com/life-science/report.php?link=intravenous-solutions

This report may help Strategists, Investors, Laboratories, Contract Research Organizations, Biotechnology & Healthcare Companies, Academic Professionals, Drug Approval Authorities, and Other Organizations to -
-Identify Market Opportunities
-Review and Analyze Global and Regional Markets
-Gauge Market Potential for your Products
-Identify Competition
-Use Market Research for exploring new areas
-Acquire Meaningful Guidelines for Strategic Planning
-Gear up for Market Entry
-Get Actionable Information

When IV solutions are produced locally in medically emerging countries, the resulting return on initial investments can be quite small. It is estimated that profitability would stand at only 50% of the total production capacity. The production costs that are incurred in developing IV solutions are 45% to 65% lower than the existing market price for primary product lines. These estimates are based on U.S. cost figures. When the U.S. system of calculation is used, both direct and indirect labor costs are the largest cost factors. However, in developing nations, the labor cost is relatively low and the cost of IV solutions is much higher. Therefore, the actual production cost can be estimated to be 60% to 90% lower than the market price of the product. There is a very high demand for IV solutions. Therefore, even if a situation arises in which production is more than the local demand, there are still excellent prospects of making national sales as well as sales through exports. The raw materials that are required to produce IV solutions are easy to procure as they are readily available in local markets.

The United States leads the global market (about 51% of global market share) for Intravenous Solutions. Due to the cost advantage and rapid increase in population, Asia-Pacific is the fastest growing market for Intravenous Solutions. Asia-Pacific and Rest of World are expected to gain significant market shares in the coming years. 

There are certain triggers that drive the growth in the global market. Some of these drivers are population growth and the continuous upgradation of health care delivery mechanisms. IV infusion therapy is increasingly playing a vital role in health care treatment modalities. This is because recent innovations in the field of antibiotics and other medications used in medical spheres such as chemotherapy, burn centers and renal/peritoneal dialysis centers support the use of intravenous solutions. Key suppliers of nutritional intravenous solutions in international markets have also developed techniques of pre-mixing nutrients that were formerly given separately to patients. Earlier pre-mixed intravenous solutions were developed for the convenience they offered. Now the question of cost has been brought into the equation. The changes in Government policies have also facilitated the development of light and portable injection devices. These are handy as patients can now receive intravenous treatments in doctor’s clinics or even in their own homes.

About RI Technologies

RI Technologies, www.researchimpact.com, is a premier market research provider. The company believes in pure research that will trigger action for immediate customer needs rather than plain reporting of data. The reports provide strategic information tools that help to probe into and support critical business decisions. RI Technologies believes in broadening the value of market research obtained through several dedicated streams of information. Investment banks, companies, management consultants, trade associations, corporate executives, business analysts, libraries, universities, and business schools stand to benefit from RI Technologies' unique market research reports.

To order this report, please contact us. You may also explore customized research services on Intravenous Solutions with RI Technologies. 

contactus@researchimpact.com

Anasuya Vemuri
RI Technologies
www.researchimpact.com
+91 9676994272
Anasuya Vemuri
RI Technologies
+91 9676994272
email us here


Tuesday 5 May 2015

Metabolomics Research and Toxicology Studies

Metabolomics - Toxicology Studies - Pharma Industry Benefits Heavily - RI Technologies' Market Research Update

In early drug development stages, Metabolomics can reduce several trial-and-error methods for pharmaceutical companies, leading to savings in costs and efforts. Metabolomics report will help Biotechnology & Healthcare Companies and Market Strategists to Identify Market Opportunities and Competition, and Know and Use Market Research for Exploring New Areas. 

For the past few years, the most commonly used methodologies in systems biology for exploring drug discovery have been genomics and proteomics. Now, metabolomics complements these two methods offering scientists a powerful tool that can uncover enormous amounts of information. The main difference between genomics/proteomics and metabolomics is that while the earlier methods studied genes and proteins, metabolomics focuses on metabolites, which are the substrates and end products of enzymatic reactions. Metabolites are compounds of low molecular weight, which determine the unique characteristics (phenotype) of an organism. This facilitates the identification of specific biological conditions, whether they are healthy or diseased.
While work on detecting and quantifying several metabolites has been continuing for decades, it is only now that scientists are able to compile a complete metabolic profile of an organism. Today research in metabolomics is directed at tracing out specific metabolites corresponding with specific disease states to facilitate drug development.
Metabolomics will make a significant impact in -
  •    Development of tools and methodology for research
  •    Bioinformatics and software to facilitate collection and analysis of data
  •    Pharmaceutical organizations involved in drug discovery and development


The report is available at  
http://www.researchimpact.com/life-science/report.php?link=metabolomics

The report gives an insight into Metabolomics Technologies – Combined/Integrated Systems, Hardware Systems for metabolic analytics and Software Systems. The study includes estimates and projections for the total global metabolomics market. Projections and estimates are also illustrated by geographic region including the United States, Europe, Japan, Asia-Pacific, Canada and Rest of World. Business profiles of 28 major companies are discussed in the report. The report serves as a guide to global metabolomics industry, covering more than 400 companies that are engaged in metabolomics R&D and supply of products and services. Major Contract Research Organizations and Universities serving metabolomics industry are also covered in the Corporate Directory section of this report. Information related to recent product releases, product developments, partnerships, collaborations, and mergers and acquisitions is also covered in the report.

About RI Technologies
RI Technologies, www.researchimpact.com, is a premier market research provider. The company believes in pure research that will trigger action for immediate customer needs rather than plain reporting of data. The reports provide strategic information tools that help to probe into and support critical business decisions. RI Technologies believes in broadening the value of market research obtained through several dedicated streams of information. Investment banks, companies, management consultants, trade associations, corporate executives, business analysts, libraries, universities, and business schools stand to benefit from RI Technologies' unique market research reports.

To order this report, please contact us -

contactus@researchimpact.comAnasuya VemuriRI Technologieswww.researchimpact.com+91 9676994272
Share on  Facebook ·  Twitter ·  LinkedIn ·  Google+

Sunday 26 April 2015

ADME Toxicology Market Research

Global ADME/TOX market is mainly driven by the efforts of pharmaceutical and biotech companies for reducing time and cost of drug discovery. ADME/Tox profiling of a drug candidate plays a key role in reducing clinical trials cost and time of drug launch to the market. ADME/Tox assayseliminate compounds with lack of bioavailability, lower efficacy and toxicity in early stages, in order to save time and costs in expensive later stages of drug discovery.

RI Technologies' latest update on ADME/TOX Technologies
http://www.researchimpact.com/life-science/report.php?link=adme/tox-technologies


The current study is quite useful in choosing the right technology at the right time to conduct ADME/Tox screening of a drug candidate, to save time and money in the process of obtaining regulatory approval. ADME/Tox is a science that needs to be better understood by strategic decision makers. The risks involved and the end use applications should be major areas of research going further. ADME/Tox is considered a major hurdle in drug discovery today. Companies that produce state-of- art tools and focus on complete solutions will be clear winners. Automation is the way to go with emphasis on lower costs. Clearly, animal models cannot be totally overruled owing to the traditional concerns, and also the comfort level involved since they provide the closest biological environment to human systems.

New technologies in ADME/Tox have evolved from diverse scientific disciplines. The toughest challenge is to integrate several successful features and enable pharmaceutical companies to benefit and reap profits in the future. Though some of the concepts in this industry are still in infant stages, the data generated from other relevant sources can be used to close the gaps. Pharmaceutical companies realize the potential of ADME/Tox technologies and are trying more than before to incorporate innovative procedures to reduce drug attrition rates and lessen the burden of costs and save precious time.

Strategic partnerships between pharmaceutical and biotechnology companies are the order of the day, and the trend is increasing globally. Another significant trend is the alliance between Pharma and Biotech companies and information technology companies such as Microsoft, IBM, Oracle, Sun, and Infosys, etc. The computer platforms generated by such companies help managing and analyzing the huge amounts of data produced from ADME/Tox technologies such as High Throughput Screening (HTS) and other computational techniques. Effective R&D strategy involves efficient data management and implementation plans. The new technologies promise improved efficacy, decreased toxicity in patients, and reduced time frames and expenditures.

For more information, please contact us.
contactus@researchimpact.com
+91 9676994272



Tuesday 21 April 2015

DNA SEQUENCING MARKET RESEARCH REPORT - APRIL 2015

RI Technologies' DNA Sequencing Market research report presents an in depth analysis of DNA Sequencing market. The study emphasizes on both, the Methods and Instruments/Software of DNA Sequencing in Medical Research, Agriculture & Animal Husbandry and DNA Testing & Forensics application areas. 

Automated and Non-Automated (Sanger's, Maxam-Gilbert and Pyrosequencing) DNA Sequencing Methods are analyzed. he major Instruments/Software segments encompass Instruments (DNA Sequencers, DNA Synthesizers, DNA Sequencing Kits, and Microarray Technology) and Bio-Informatics. In depth Application analysis of Medical Research fields such as Proteomics, Pharmacogenomics and Molecular Diagnostics is also covered. The report provides essential information including market data, segmentation, market size, key trends, M&A, product developments, industry forecasts, corporate intelligence, and other relevant information. The report lists more 500 companies that are engaged in DNA Sequencing services, instrumentation, R&D and supply of products and services. A global perspective is presented along with regional analysis covering the regions of North America, Europe, Asia-Pacific, Japan and Rest of World. 

DNA is the carrier of genetic information in living organisms. It is said to be the blue print of an organism coordinating the various cellular activities and development. It regulates growth and metabolism and controls the traits, for example eye color. The order or sequence of the bases constitutes the specific instruction for a trait or activity. For example, the sequence ATCGTT may code for blue eye color and ATCGCT may express into brown eye color. But complex traits like intelligence appear to be influenced partly by inheritance and partly by environmental condition. The introduction of DNA sequencing has extensively accelerated the pace of biological research and various discoveries. The quick pace of sequencing can easily be achieved by employing sophisticated modern DNA sequencing technology. This has enabled the large-scale sequencing of the human genome, which is part of the Human Genome Project. The numerous related projects by scientific collaboration have succeeded in generating the complete DNA sequences of for many plants, animals and microbial genomes across the globe. g prominence because it offers a ray of hope for those afflicted with genetic disorders.

For more information on this report, please view



Sunday 5 April 2015

Biotech Market Research Reports - April 2015 - Updates from RI Technologies

Market research reports need continuous updations to help readers get the latest information. As part of its updation program, RI Technologies has updated its entire portfolio of biotech and healthcare related market research reports. The company's latest press release - 

http://www.pressat.co.uk/releases/biotechnology-and-healthcare-market-research-reports-2nd-quarter-2015-latest-updates-from-ri-technologies-ede850c1972932065a4a47f32e178f30/

RI Technologies updates its reports periodically to stay ahead in the market and provide latest corporate and industry information.

Biotechnology and healthcare related market research studies are available at -

http://www.researchimpact.com/life-science/

For more information you may please contact our help desk at contactus@researchimpact.com
Phone: +91 9676994272
www.researchimpact.com